Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant‑eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
10.1007/s44313-025-00097-z
- Author:
Jun Ho YI
1
;
Young Hoon PARK
;
Myung‑won LEE
;
Kwai Han YOO
;
Junshik HONG
;
Hyeon‑Seok EOM
Author Information
1. Division of Hematology‑Oncology, Department of Medicine, Samsung Medi‑ cal Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:RESEARCH
- From:Blood Research
2025;60():62-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Brentuximab vedotin (BV)-based combinations have shown promising results in patients with relapsed or refractory Hodgkin’s lymphoma (RRHL) in Western countries. We conducted a phase II study to further define the role of BV-based salvage therapy in transplant-eligible patients with RRHL in Korea.
Methods:Transplant-eligible patients with RRHL were recruited to receive two cycles of BV (1.8 mg/kg) plus DHAP (cisplatin 100 mg/m2 , cytarabine 2 g/m2/sup> , and dexamethasone 40 mg). Autologous stem cells were collected from non-progressive patients who received one more cycle of BV-DHAP. After three cycles, the responding patients underwent autologous stem cell transplantation (ASCT). The primary endpoint was a complete metabolic response (CMR) rate after two cycles of BV-DHAP.
Results:Between April 2022 and August 2024, seven lymphoma cases were recruited. Owing to slow accrual, the study was terminated early. Their median age was 30 years (range, 24–62 years). All patients received at least two cycles of BV-DHAP; the overall response rate (ORR) was 100%, and four patients showed CMR (57%). One patient with‑ drew consent after the second cycle, and the other six patients received one more cycle of BV-DHAP, resulting in five patients achieving CMR (71%). One patient failed to receive ASCT, and all five patients who received ASCT achieved post-transplant CMR with a 80% complete response (CR) over a 12-month duration. Thrombocytopenia was the most common grade 3 or higher grade hematologic adverse events (n = 5). Grade 2 nausea occurred in three patients.Three patients experienced dose reduction, and four patients experienced treatment delays.
Conclusions:Despite its encouraging early efficacy, the administration of BV-DHAP in Korean patients with RRHL requires careful monitoring due to toxicity concerns.
